IOVA
Iovance Biotherapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.37B
P/E Ratio
—
EPS
$-1.09
Beta
0.76
52W High
$5.63
52W Low
$1.64
50-Day MA
$3.41
200-Day MA
$2.60
Dividend Yield
—
Profit Margin
-148.40%
Forward P/E
—
PEG Ratio
0.00
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Fundamentals
| Revenue (TTM) | $263.50M |
| Gross Profit (TTM) | $90.32M |
| EBITDA | $-362.27M |
| Operating Margin | -84.70% |
| Return on Equity | -55.50% |
| Return on Assets | -27.30% |
| Revenue/Share (TTM) | $0.74 |
| Book Value | $1.70 |
| Price-to-Book | 2.02 |
| Price-to-Sales (TTM) | 5.19 |
| EV/Revenue | 4.423 |
| EV/EBITDA | -8.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 17.70% |
| Shares Outstanding | $411.96M |
| Float | $353.41M |
| % Insiders | 0.40% |
| % Institutions | 71.04% |
Analyst Ratings
Consensus ($9.00 target)
2
Strong Buy6
Buy3
HoldData last updated: 4/8/2026